Big Pharma pushes new migraine drugs into Phase III with blockbuster hopes

Damian Garde

A cadre of drugmakers is pressing toward late-stage trials with new injectable treatments in the long-stagnant field of therapy, racing to capitalize on what analysts say is a multibillion-dollar market.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS